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Background: In 2007, the World Health Organization (WHO) launched the ‘make medicines child size’ (MMCS)
campaign by urging countries to prioritize procurement of medicines with appropriate strengths for children’s age
and weight and, in child-friendly formulations of rectal and flexible oral solid formulations. This study examined
policy provisions for MMCS recommendations in Uganda.
Methods: This was an in-depth case study of the Ugandan health policy documents to assess provisions for MMCS
recommendations in respect to oral and rectal medicine formulations for malaria, pneumonia and diarrhea, the
major causes of morbidity and mortality among children in Uganda- diseases that were also emphasized in the
MMCS campaign. Asthma and epilepsy were included as conditions that require long term care. Schistomiasis was
included as a neglected tropical disease. Content analysis was used to assess evidence of policy provisions for the
MMCS recommendations.
Results: For most medicines for the selected diseases, appropriate strength for children’s age and weight was
addressed especially in the EMHSLU 2012. However, policy documents neither referred to ‘child size medicines’
concept nor provided for flexible oral solid dosage formulations like dispersible tablets, pellets and granules- indicating
limited adherence to MMCS recommendations. Some of the medicines recommended in the clinical guidelines as first
line treatment for malaria and pneumonia among children were not evidence-based.
Conclusion: The Ugandan health policy documents reflected limited adherence to the MMCS recommendations. This
and failure to use evidence based medicines may result into treatment failure and or death. A revision of the current
policies and guidelines to better reflect ‘child size’, child appropriate and evidence based medicines for children is
recommended.
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The need for appropriate medicines for children has
attracted attention worldwide [1-5]. It is argued that ap-
propriate medicine formulations should be the basis for
drug therapy for children to ensure efficacy and safety
[5,6]. Unsuitable formulations may lead to the child not
taking the medicines, or receiving inappropriate doses
leading to adverse reactions or ineffective treatment [7],
needless to mention death. Many formulations used for
children, especially tablets, are inappropriate for dosing,* Correspondence: dianatim2001@yahoo.co.uk
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unless otherwise stated.dispensing and administering [8]. For example, tablets for
adults have traditionally been split and given to children,
resulting in inaccurate doses in view of the children’s
weight, age, physiological and cognitive conditions [9].
The World Health Organization in 2007, launched the
‘make medicines child size’ (MMCS) campaign to ensure
that children receive the right medicine in the right
dose. The MMCS initiative defined ‘child size medicines’
as those with: appropriate strengths and, child-friendly
characteristics such as suppositories, solutions and flexible
solid oral dosage formulations [10]. The United Nations
(UN) member states were urged to make the procurement
and supply of ‘child size medicines’ a priority and also
ensure that there are corresponding legislative andntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dren [11]. WHO also accentuated the importance of
children’s medicines being based on the recent evidence
of efficacy and safety for treating the specified children
[10]. Flexible solid oral dosage forms are considered
most suitable for children at the global level especially
for developing countries [12]. The flexible solid oral
dosage forms include tablets that are dispersible and
can be used for preparation of oral liquids suitable for
the younger age groups, powders, granules and pellets
[10]. Evidence based medicine has been defined by
Dickerson and others as a healthcare practice that is
based on integrating knowledge gained from the best
available research evidence, clinical expertise, patients'
values and circumstances [13]. In 2011, WHO, with
support from the United Nations Fund for Population
Activities (UNFPA) and United Nations International
Children’s Emergency Fund (UNICEF) proposed a list
of lifesaving priority medicines for mothers and chil-
dren to reduce maternal, new born and under five mor-
bidity and mortality [14,15].
The role of policy provisions in increasing children’s
access to appropriate medicines, as recommended by the
MMCS campaign, cannot be underestimated. The need
for country level reviews about the status of pharma-
ceutical policies, practices and the degree to which these
policies are adhered to has been underscored [16]. It has
been argued that evaluation of national medicine policies
has potential for creation of evidence that other coun-
tries can use to formulate similar policies in their set-
tings [17].
A study of provisions for priority medicines for
mothers and children in the national essential medicines’
lists concluded that countries need to urgently amend
their lists to provide all priority medicines as part of the
efforts to improve maternal and child health [18]. Stud-
ies about the implementation of ‘child size medicine’
policies at country levels have been scarce. A survey by
WHO in 14 African countries recommended an im-
provement of access to medicines for children [19]. In
Tanzania, it was reported that caretakers experienced
problems in administering tablets whereby the children
either disliked the taste or vomited the medicines [20].
A study on provisions for safe medicines for children in
Nigeria, on the other hand, found that there was a lack
of paediatric focus in the essential medicines lists, a lack
of access to up-to-date medicine information and weak
national level policies [21].
There have been variations in the definition of policy.
However, policy is commonly referred to as: formal
authorization [22] norms, values and power [23] or
‘course of action that affects a set of institutions, organi-
zations, services and funding arrangements [24]. This
study collectively refers to policy statements, strategies,lists of essential medicines and clinical guidelines as ‘pol-
icy documents’.
In Uganda, the essential medicines management pro-
gram has been in place since 1985 [25] and has been in-
fluential in determining the medicines that are procured
by public health facilities. Over the years, this program
has evolved and is the origin of policy provisions like the
essential medicines lists and clinical guidelines. Prior to
and after the launch of the MMCS campaign, no studies
tailored to policy provisions for child size medicines in
Uganda existed. Although the medicine policy reforms
affecting essential medicines lists and clinical guidelines
have been introduced, it is not clear to what extent they
have addressed the MMCS recommendations. The ob-
jective of this study was to investigate the policy provi-
sions for MMCS campaign by WHO in Uganda and
make recommendations on how to address the policy
gaps, if any.Methods
Study setting
Uganda is a low income African country with population
of 34.9 million according to the population and housing
census conducted recently [26]. The under-five mortality
rate is 90 per 1000 live births and the infant mortality
rate is 54 per 1000 live births [27]. The National Medical
Stores (NMS) is an autonomous government department
that procures and distributes medicines to public facil-
ities. Another key distributor of medicines is the Joint
Medical Stores (JMS) - an umbrella organization for the
Uganda Catholic and Uganda Protestant medical bur-
eaus. However, donor funded programs for malaria, the
Integrated Community Case Management of fever
(ICCM), HIV/AIDS and tuberculosis, also procure and
distribute medicines.
The health care system is organized under a hierarchy
of health facilities, the lowest being Health Centre I
(HC I) and highest being the National Referral Hospital. A
Health Centre I (HC I) is a village facility with no defined
physical structure where community out-reach services
take place. HC I is managed by the Village Health Team
(VHT) volunteers who do health promotions, distribute
some medicines and mobilise communities for utilization
of health services. A Health Centre II (HC II) is the phys-
ical health service structure closest to the community that
provides basic curative services. A Health Centre III (HC
III) is a little more comprehensive than HC II providing
basic preventive and curative care services, handles refer-
rals from the HC II, but also refers to HC IV. A Health
Centre IV (HC IV) is a mini hospital with a simple theatre
for minor surgeries covering a population equivalent to a
constituency. In the Ugandan decentralized system, this is
referred to as the Health Sub-District (HSD). Above this
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hospitals.
Study design
The key methodological approach was an empirical
one: a review of 10 selected Ministry of Health policy
documents. This was an in-depth case study of policy
documents in Uganda whereby archived documents
were retrieved from the Ugandan Ministry of Health
(MOH) and development partners. The documents
were reviewed to empirically verify the policy provi-
sions for ‘child size medicines’. Initially, it was realised
that there was no single MOH official with an overview
of the relevant policy documents that would address
our research question. There was no single office (includ-
ing the MOH resource centre) that had an inventory of all
the documents in one place. Therefore, the relevant policy
documents were identified using a rigorous process of
consultation with Ministry of Health officials, institutions
and officials from the relevant departments, donor com-
munity and other development partners. Institutions
consulted included the Child Health Division and Phar-
macy departments of the MOH, NMS, JMS, National
Drugs Authority (NDA), Malaria Consortium (MC),
WHO, UNICEF, Securing Ugandan’s rights to Essential
medicines (SURE) and STRIDES for family health.
Other sources included libraries, resource centres of
workers, archives in the MOH resource centre (the li-
brary and information centre) and references of rele-
vant published literature.
The internet was searched including the Uganda MOH
website [28]. On the MOH website, there was a section la-
belled ‘policy documents & guidelines’ with a link to the
ministry’s publications. Search terms included: child size
medicines, paediatric formulations, child-friendly medi-
cines, treatment guidelines, policy statements, strategic
plans, clinical guidelines and essential medicines lists.
Guidelines of child health programs such as Integrated
Management of Childhood Illnesses (IMCI), Integrated
Community Case Management (ICCM) and malaria treat-
ment policy guidelines were also scrutinized.
The criteria for inclusion of documents for further
analysis were whether they covered the aspects of medi-
cines for tracer conditions considered in the study, med-
icines used to treat these conditions, their dosage
formulations and whether they were developed by or in
partnership with the government between the year 2007
and 2013. Overall, twenty four documents were retrieved
because their titles, headings and contents were found
relevant using the quality control criteria of authenticity,
credibility, representativeness and meaning as discussed
by Scott [29]. However, only 10 documents qualified for
further review after checking whether they mentioned
child-size medicines, whether medicines they mentionedwere child appropriate with strengths adjusted to chil-
dren’s age and weight.
Data analysis
Content analysis was used to assess provisions for ‘child
size medicines’ and child-friendly formulations. The doc-
uments were checked for information about ‘child size
medicine’ concept, medicines strengths for children
based on scientific evidence, flexible oral dosage forms,
dispersible and effervescent tablets, solutions, syrups
and suppositories. Also considered were provisions for
medicines for malaria, pneumonia and diarrhoea being
the major causes of childhood morbidity and mortality
in Uganda and being the key target diseases for the
MMCS campaign [30]. Asthma and epilepsy were in-
cluded because they are among the most common
chronic childhood conditions in Uganda requiring long
term management. Schistomiasis was considered as a
neglected tropical disease with high prevalence in more
than half of the districts in Uganda yet prevalence of the
disease among preschool children is at 39.3% according
to a recent study [31]. In this paper, we refer to these
diseases as ‘tracer conditions’. We only included oral, in-
haled and rectal formulations that are commonly pre-
scribed to babies and usually administered by caretakers.
The study excluded injectables because they are for spe-
cific disease severity and are administered by more
trained personnel at different levels of health care.
All these content considerations were first combined
into an assessment matrix which was finally translated
into Tables 1, 2 and 3 developed in consultation with
paediatricians and dispensers from Mulago National
Referral Hospital. We applied the elements in the matrix
to the documents, the medicines for the tracer condi-
tions and the medicines recommended as vital for the
various levels of the public health facilities in Uganda as
reflected in Tables 1, 2 and 3.
Ethical considerations
The study was approved by the Higher Degrees, Re-
search and Ethics Committee of Makerere University
College of Health Sciences (MakCHS) and the Uganda
National Council of Science and Technology (Ref: SS
2703). The heads of the respective department in the
MOH and development partners who gave verbal per-
mission to access the documents.
Results
Historical overview of the reforms
The results indicate that since 2007, Uganda had revised
the Clinical Guidelines (UCG) twice, in 2010 and in
2012. The guidelines for Integrated Community Case
Management (ICCM) of childhood illnesses were intro-
duced in 2010. In 2012, a new essential medicines and
Table 1 Documents identified and their provisions for elements of ‘child size medicines’




The second National Health Policy (NHP II 2012/19) 2012 - -
The Health Sector Strategic and Investment Plan 2010/11-2014/15 2010 - +1
Health Sector Ministerial Policy Statement-FY2010 and 2011 2010 - -
National Drug Authority Uganda Strategic Plan 2011-2015 2011 - +2
Integrated Community Case Management of Childhood Malaria,
Pneumonia and Diarrhoea: Implementation Guidelines
2010 - +
The Uganda Clinical Guidelines 2010 + -
The Uganda Clinical Guidelines 2012 + -
The IMCI guidelines: Management of a sick child aged 2 months
up to 5 years
−3 - -
The Essential Medicine and Health Supplies List (EMHSLU) 2012 + +
User’s Mannual: Use of Rapid Diagnostic Tests (RDTs) for Malaria
in fever case management in Uganda.
2012 + +
1The Health Sector strategic plan refers to the distribution of amoxicillin in the community by the village health team members. Amoxicillin is an evidence
based medicine.
2National Drug Authority is referring to medicines that have been phased out such as chloroquine and fancidar in relation to treatment of malaria.
3This is a treatment chart for IMCI which has not been revised since 2002.
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duced. The EMHSLU 2012 was differentiated from the
Essential Medicines List 2007 by the introduction of es-
sential health supplies component and the Vital Essen-
tial and Necessary (VEN) classification of medicines.
The “Vital” (V) medicines are used to manage life-
threatening diseases, “Essential” (E) medicines are ef-
fective in management of less severe, but nevertheless,
widespread illnesses and “Necessary” (N) medicines are
used to treat diseases with less impact on the popula-
tion or items with a high cost for marginal therapeutic
benefit. The overall purpose for introducing the VEN
classification was to enable health facility and ministry
of health procurement officials to prioritize medicinesTable 2 Child size medicines provisions for tracer conditions
of Uganda












Salbutamol nebulizer solution +
Schistomiasis Praziquantel -to procure. All these medicine reforms after 2007 were
opportunities for addressing the requirements of the
MMCS campaign.
Table 1 provides a list of the 10 documents that were
reviewed. None of the documents made reference to the
‘child size medicine’ concept. However, elements of med-
icines strengths appropriate for children were included
in the EMHSLU 2012. Flexible oral dosage forms such
as dispersible tablets were missing in the EMHSLU 2012
for all the medicines for the tracer conditions except for
zinc sulphate effervescent tablet for diarrhoea. The
National Drug Authority strategic plan only highlighted
some medicines that had been phased out from the list
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2010 and 2012 had been phased out by the National
Drug Authority (NDA). The EMHSLU and UCG emerged
as the only documents with much content about children’s
medicines.
The essential medicines lists
The EMHSLU 2012 does not mention ‘child size medi-
cines’ specifically. A further examination was done to
establish whether the EMHSLU included aspects of child-
friendly formulations such as dispersible tablets, efferves-
cent tablets, inhaler solutions, syrups, suppositories and
medicines strengths for children.
Child-friendly medicines
The EMHSLU had limited provisions for child-friendly
dosage formulations for medicines for each of the tracer
conditions studied. According to Table 2, four out of the
12 medicines assessed were in child-friendly dosage for-
mulations. These included rectal artesunate for malaria,
ORS for diarrhoea, zinc sulphate effervescent tablet and
carbamazepine syrup for epilepsy. None of the medicines
for pneumonia, malaria and schistomiasis were in flex-
ible oral solid dosage forms such as dispersible tablets. It
should be noted that syrups (which are child-friendly in
terms of administration) for malaria and pneumonia that
were in the 2007 EML were excluded in the EMHSLU
2012. Rectal artesunate which uses a child-friendly chan-
nel of drug administration was provided for in the
EMHSLU and was appropriate for its purpose of pre-
referral emergency treatment. The medicines for asthma









Amoxicillin _ + HCII and above
Cotrimoxazole - + HC II and above
Artesunate - + HC I and HCII
Artemether lumefantrine - + HC II
Zinc sulphate + + HC I and HCII
ORS + + HC I and HCII
Praziquantel - - None
Prednisolone - + None
Salbutamol + + HC IV
Carbamazepine tablets - + HC IV
Carbamazepine syrup + + HC IVwhich are child-friendly and the recommended method
of administration of asthma medicines. However, it was
noted that the spacers, that are supposed to be used in
administering the inhalations to the children, were not
included in the health supplies section of the EMHSLU
2012.Appropriate medicine strengths for children
Appropriate medicine strengths for children were present
in both the Essential Medicines List (EML) 2007 and
EMHSLU 2012. Table 2 shows that 10 of the 12 medicines
(83%) assessed for the tracer conditions in the EMHSLU
2012 had appropriate strengths for children. The excep-
tions were quinine for malaria and praziquantel for
schistomiasis.VEN classification
As already indicated, the EMHSLU 2012 introduced the
concept of Vital, Essential and Necessary (VEN) Classifi-
cation. The VEN classification was established to help fa-
cilities prioritize medicines to order, considering the often
limited funding that they have been allocated. Table 3
shows the ‘child size medicine’ formulations that were
classified as ‘vital’ according to the different healthcare fa-
cilities. Here it must be mentioned that amoxicillin and
artemether-lumefantrine were also recommended for the
ICCM program at HC I (village level facilities). All the
child-friendly medicines including carbamazepine syrup,
rectal artesunate, zinc sulphate dispersible tablets and oral
rehydration salts (ORS), were classified as vital for the





Dispersible amoxicillin is provided at HC1 by the development
partners. Although HC1 is not included in the VEN classification,
amoxicillin is distributed there
Cotrimoxazole which is not evidence based is the
recommended first line for pneumonia in public facilities
Both an injectable and rectal
Dispersible Artemether lumefantrine is supplied by malaria
consortium and UNICEF at HCI
Is provided at HC1 by the development partners
Is provided at HC1 by the development partners
Praziquantel is mainly provided for adults in the community and
schools through mass drug administration. Children below
school going age are not included in the distribution
Asthma cases are also handled at the lower level health facilities
Epilepsy cases are also handled at the lower level health facilities
Same as above
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The guidelines recommended splitting of adults’ tablets
for children. Furthermore, some of the medicines rec-
ommended for treatment of malaria and pneumonia
among children were evidence based medicines.
Recommendation of splitting of adult medicines to give
to children
Two editions of the Uganda Clinical Guidelines (UCG)
were reviewed (2010 and 2012) and in both documents,
a specific section on IMCI was included. In terms of
dosage the UCG 2010 still emphasized the need for
breaking adult medicines according to age and weight:
“For children who are 12 years and less, the guidelines
recommend that: the dose should be stated in terms
of body weight; where weighing is not possible, doses
should be approximated from adult doses: < 5 years ¼
of the adult dose, 5–8 years ½ of adult dose and 9–12
years ¾ of the adult dose. In this case, it is anticipated
that Health workers will weigh the child and calculate
the dose based on the weight. It also means that in
case of administering tablets, they have to determine
what portion of the tablet is to be given to the child”
(UCG 2010: xxiv-xxv) [31].
Evidence based medicines
Some of the medicines recommended in the clinical
guidelines as first line treatment for malaria and pneumo-
nia were not evidence-based and there were discrepancies
across the different sections of the guidelines. For ex-
ample, in the IMCI section of UCG out dated medicines
such as a combination therapy of chloroquine and sul-
phadoxine pyrimethamine (CQ + SP) was recommended
for malaria, while cotrimoxazole was recommended for
pneumonia. On the other hand, in the general section of
UCG 2010, the evidence based Artemether based combi-
nations (ACTS) were recommended for malaria among
children less than five years. In the IMCI section of the
same guidelines, a combination of CQ and SP was recom-
mended and yet by the time of this study, oral chloroquine
and sulphadoxine pyrimethamine had been phased out as
medicines for treating malaria. Both the 2010 and 2012
versions of the UCG recommended cotrimoxazole as first
line treatment for pneumonia in spite of the ICCM guide-
lines recommending amoxicillin for the treatment of
pneumonia. These discrepancies within the UCG and
other policy documents such as the ICCM guidelines
demonstrate lack of harmonization of the policy docu-
ments regarding evidenced based medicines.
Discussion
The policy documents did not mention the ‘child
size medicines’ concept anywhere, indicating a lack ofadequate and specific attention to the MMCS recom-
mendations. While the problem of medicine strengths
according to age and weight of the child had been ad-
dressed in the EMHSLU and partly the UCG, there
were no provisions for the WHO recommended flexible
oral solid dosage forms (except for zinc sulphate efferves-
cent tablet for treating diarrhoea) for easy administration
of the medicines to children. Some of the medicines rec-
ommended in the clinical guidelines for malaria and pneu-
monia were not evidence based, demonstrating gaps in
policy provisions for appropriate medicines for children in
Uganda.
The WHO recommendations on child-size medicines
remain an unfinished business
There was no explicit reference to the ‘child size’ medi-
cine concept in the Ugandan health policy documents.
While there are 17 varieties of oral paediatric formula-
tions which are ready-to-use at the global level [4] and
whereas professional organizations, the pharmaceutical
industry, and some governments from high income
countries have emphasized ‘child size medicine,’ there is
no such emphasis in low income settings like Uganda.
Only three low income countries (Ghana, India and
Tanzania) worldwide have been supported to pilot MMCS
by Bill and Melinda Gates Foundation [12]. Hence, there
are no experiences and guidelines for scale up of the
‘child size medicine concept’ and child appropriate for-
mulations in other low income countries.
Flexible oral solid dosage forms have been recom-
mended as the most appropriate for children since they
allow accurate dosing and easy administration of medi-
cines to children [7]. For example, all the lifesaving pri-
ority medicines in tablet forms are supposed to be in
flexible oral solid dosage formulations such as dispers-
ible tablets [14,15]. In the EMHSLU 2012, none of the
medicines for malaria and pneumonia were presented in
flexible solid oral dosage forms such as pellets, granules
and dispersible tablets. This could lead to ineffectiveness
of the treatment [32]. The omission of dispersible tablets
for artemether- lumefantrine (for malaria) and amoxicil-
lin (for pneumonia) in the EMHSLU is a critical gap
since the two diseases are the main causes of morbidity
and mortality in Uganda. Despite amoxicillin being an
efficacious medicine for pneumonia which is the leading
killer disease in children world-wide and in Uganda, and
despite the recommendation that it should be provided
as a scored dispersible tablet in order to optimize the
benefits [15], this has not been the case in Uganda.
An analysis demonstrated that the medicine for diar-
rhoea specifically ORS (powder) and zinc (effervescent
tablet) which were included in the medicines EMHSLU
2012 were not only evidence based but were also in flex-
ible oral solid dosage forms. WHO and UNICEF have
Nsabagasani et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:2 Page 7 of 9listed zinc sulphate effervescent tablets and ORS among
the priority medicines for children with diarrhoea
[14,15]. However, it has not been established whether
these medicines are available in the health facilities in
Uganda or not. Asthma medicines such as oral predini-
solone are not in a flexible oral solid dosage forms and,
depending on the age and weight, they may require the
child to swallow several bitter tablets at a time.
Medicine strengths for children
One of the important study findings was that except for
praziquantel, a distinction has been made between medi-
cines strengths for adults and those of children, espe-
cially in the EMHSLU 2012. Therefore, except in very
exceptional cases, in future there will no longer be need
to split adult tablets to determine the appropriate dose
for children as has been widely professed in the litera-
ture. The remaining question is whether the medicines
with strength for children are being procured and made
available.
While the medicine strength suitable for children has
been provided for, there is still a challenge of children
swallowing formulations that are not child-friendly and
flexible. This is because the current clinical guidelines
still emphasize the practice of splitting adult medicines to
treat children. This demonstrates a lack of harmonization
between the guidelines and the essential medicines list-
two documents that are supposed to complement each
other.
Praziquantel which is used to treat schistomiasis has
been presented in an adult strength only. This is despite
of the fact that schistomiasis has been highlighted by
WHO as one of the priority neglected tropical diseases,
with an existent prerequisite to focus on children’s
needs. However, despite the presence of tablets with
strengths adjusted to children in the world market [6],
the 600 mg tablet of praziquantel still remains the only
dose available for treating schistomiasis for both adults
and children in Uganda. In most of the sub Saharan
Africa, schistomiasis is treated through Mass Drug
Administration (MDA) programs to adult populations
and children in schools. Although schistomiasis preva-
lence has been established in the age group below four
years, little has been done to provide appropriate medicine
for this age group [6]. In terms of medicines strengths,
there are no provisions of praziquantel for the lower
age categories. In Uganda, a low uptake of praziquantel
among school children, due to side effects, unpalatable
taste and the big tablet size has been reported [33,34].
Evidence based medicines
Inconsistencies in the sections of the clinical guidelines,
especially regarding recommendations of medicines that
have already been phased out due to resistance werenoted. These inconsistencies often leave health workers
confused since for the case of Uganda, those who pro-
vide services at the lower levels of health care are inad-
equately trained and for that reason they largely depend
on the guidelines to treat.
Cotrimoxazole was recommended as the first line
treatment for pneumonia although studies have shown
that it is no longer effective, especially in high HIV
prevalence settings including Uganda [35,36]. Amoxicillin
which is recommended by the WHO as the most effective
antibiotic for pneumonia, is a second line treatment in
Uganda and is only used as first line if there is a wheezing
problem [37]. According to UNICEF, 1.56 million lives of
children could be saved globally if amoxicillin was avail-
able [38]. Similarly, a combination of chloroquine and
sulphadoxine pyrimethamine was recommended for treat-
ment of malaria yet it is no longer effective. Therefore
there is need for due diligence in terms of providing rele-
vant and accurate guidelines, increasing access to effica-
cious and child-friendly medicines. This can be achieved
when there are policy provisions for evidence based
medicines.Study strengths and limitations
Study strengths The scope of this study was the period
from 2007–2013. This provided an ample time of 6 years
since the launch of WHO/UNICEF campaign for coun-
tries like Uganda to operationalize the concept at the na-
tional level. In the same period, some medicine reforms
such as the revision of clinical guideline and essential
medicines list 2012 took place and this was an oppor-
tunity to assess whether the reforms integrated the rec-
ommendations of the MMCS campaign. This was a case
study on Ugandan policy documents. The study also dis-
covered that document analysis could be a stand-alone
qualitative method of research [39,40]. Case study de-
signs have been recommended for an in-depth analysis
of the policies and be replicable to other situations [41].
Policy documents are critical for understanding the pol-
icy direction and implementation. Since the launch of
the MMCS campaign in 2007, very few case studies
using policy document review as a method of analysis
have been done. Using the approach, this study contrib-
utes considerably to the understanding of the extent of
policy provisions for ‘child size’ medicine in a low in-
come country like Uganda.
The importance of essential medicines policies on the
quality of medicines in low-income countries has been
underscored [42]. This reiterates our emphasis about the
need to address the existing gaps in provisions of child-
size and child appropriate medicines in the EMHSLU
and the UCG. A study in Nigeria indicated that weak na-
tional policies negatively affected access to appropriate
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was one of the key documents from which the derived
substantial information to verify provisions for MMCS
recommendations. The concept of essential medicines
lists has been accepted worldwide as a powerful tool to
promoting health equity and its impact is remarkable, as
the essential medicines have proved to be one of the
most cost-effective elements in health care. Lists of es-
sential medicines also guide the procurement and supply
of medicines in the public sector, schemes that reim-
burse medicine costs, medicine donations and local
medicine production, and, furthermore, are widely used
as information and education tools by health professionals
[43]. At the global level, including high income countries,
the WHO’s campaign ‘make medicines child size’ has pro-
duced substantive accomplishments in building improved
foundations to improve mechanisms that will enhance
children’s access to critical medicines in resource-limited
settings. However, there continues to be a challenge of a
sustained, programmatic commitment especially in low
income countries [44].
Limitations From this review of documents, it was not
possible to determine the rationale for the selection of
the medicines in the essential medicines list and the ex-
tent of their availability and utilization at health facilities.
To this end, studies focusing on stakeholder perspectives
on the choice of children’s medicines, the extent to
which such medicines are available at a health facility
level and caretakers’ experiences about child size medi-
cines are needed. Studies will also be needed to assess
the availability of ‘child size medicines’ at the health fa-
cilities. More studies are needed to explore care givers’
experiences in administering some of the available child
size medicines.
A major limitation for this study was lack of existing
global standard criteria for assessing ‘child size medi-
cines’. We therefore recommend that more detailed and
standardized criteria should be developed for streamlin-
ing of the ‘child size medicines’ in different settings. This
would help in future to ensure that the medicines pro-
vided in policy documents and operational guidelines
are ‘child size’. Such an index could be based on the
WHO preliminary requests [45] which at the moment
do not provide sufficient guidance.
Injections were also left out which are also important
and highly utilized by healthcare staff in the management
of childhood illnesses. We therefore recommend add-
itional studies focusing on injections for children to try
and establish how child friendly and staff friendly they are.
Policy implications
Failure to integrate the MMCS recommendations into the
essential medicines lists and clinical guidelines impliesthat many of the children are not accessing appropriate
medicines and hence appropriate treatment. This might
result in disease severity, needless to mention the persist-
ent high mortality rate. Lack of child-friendly formulations
such as flexible oral solid dosage forms and syrups affect
the optimisation of treatment of children and for long
term medication scenarios, this might lead to resentment
that may in turn lead to further complications. Hence this
study advocates for a medicine policy framework that
addresses these problems specifically.
Conclusion
The study has shown that the concept of the child size
medicines is not explicitly reflected in the policy docu-
ments and this undermines its implementation; and hence
efforts towards reducing under-five mortality. This might
explain why the aspect of the flexible oral solid dosage
forms is not taken care of especially regarding medicines
for malaria and pneumonia, the main killer diseases in
children in Uganda. Since medicine strengths for children
have now been addressed, it is foreseen that splitting adult
tablets to give to children will reduce with time, especially
if the essential medicine list is followed during procure-
ment of medicines and clinical guidelines are revised.
Recommendations
There is an urgent need for the Ministry of Health,
Uganda, WHO and UNICEF to review why the ‘child
size medicine’ concept has not been fully implemented,
with a view of providing further guidance. There is also
a need to identify and integrate more flexible oral solid
dosage forms for the vital medicines for children includ-
ing antibiotics for pneumonia, medicines for malaria,
diarrhoea and schistomiasis, into the essential medicines
list. These formulations can be in the form of dispersible
tablets, pellets and granules in the essential medicines
list. There is also need to regularly update the essential
medicines lists and the clinical guidelines with evidence
based medicines and to further harmonise the diverse
guidelines used by health workers especially the IMCI
charts, to avoid misleading information.
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